Anti-Denosumab Neutralizing Antibody ELISA kit

Catalog No.

KAA30351

Detection method

Colorimetric

Sample type

Plasma, Serum

Assay type

Quantitative

Range

15.625-1,000 ng/ml

Precision

CV<20%

Recovery

80-120%

Shipping

2-8 ℃

Stability and Storage

The stability of ELISA kit is determined by the loss rate of activity. The loss rate of this kit is less than 10% prior to the expiration date under appropriate storage condition.

Alternative Names

AMG162, HL2001, CAS: 615258-40-7

Evaluation of Anti-SARS-CoV-2 IgG Responses in a Clinical Study of a Biosimilar Candidate to Denosumab Using Singlicate Analysis., PMID:40408051

Inhibition of RANKL is critical for accurate assessment of anti-drug antibody incidence to denosumab in clinical studies., PMID:40220951

A multicenter, randomized, double-blind trial comparing LY01011, a biosimilar, with denosumab (Xgeva®) in patients with bone metastasis from solid tumors., PMID:39995685

SB16 versus reference denosumab in postmenopausal women with osteoporosis: 18-month outcomes of a phase III randomized clinical trial., PMID:39674388

Asymptomatic Hypocalcemia Related to Denosumab Administration in Bone-Metastatic Patient Affected by Colorectal Cancer: A Case Report., PMID:39639476

The RANK-RANKL-OPG System: A Multifaceted Regulator of Homeostasis, Immunity, and Cancer., PMID:37893470

A randomized trial comparing LY01011, biosimilar candidate, with the reference product denosumab (Xgeva®) in healthy Chinese subjects., PMID:37701913

Current comprehensive understanding of denosumab (the RANKL neutralizing antibody) in the treatment of bone metastasis of malignant tumors, including pharmacological mechanism and clinical trials., PMID:36860316

Discontinuation of PTH therapy amplifies bone loss by increasing oxidative stress: An event ameliorated by sequential IL-17 neutralizing antibody therapy., PMID:34839260

Discovery of the RANKL/RANK/OPG system., PMID:33389131

Safety and pharmacokinetics of a biosimilar of denosumab (KN012): Phase 1 and bioequivalence study in healthy Chinese subjects., PMID:33306418

RANKL as a target for the treatment of osteoporosis., PMID:33057808

Inhibition of NK Reactivity Against Solid Tumors by Platelet-Derived RANKL., PMID:30813611

[The mechanism of anti-RANKL antibody in the treatment of metabolic bone diseases including osteoporosis - possible applications of anti-RANKL antibody to the treatment of cancer patients]., PMID:30643086

Anabolic Therapies in Osteoporosis and Bone Regeneration., PMID:30587780

Activation of RANK/RANKL/OPG Pathway Is Involved in the Pathophysiology of Fibrous Dysplasia and Associated With Disease Burden., PMID:30496606

Effectiveness of denosumab on back pain-related disability and quality-of-life in patients with vertebral fragility fractures., PMID:30406685

New and emerging concepts in the use of denosumab for the treatment of osteoporosis., PMID:30386439

Possible targets to treat myeloma-related osteoclastogenesis., PMID:29495905

BRCA1 haploinsufficiency cell-autonomously activates RANKL expression and generates denosumab-responsive breast cancer-initiating cells., PMID:28388533

Functional block of IL-17 cytokine promotes bone healing by augmenting FOXO1 and ATF4 activity in cortical bone defect model., PMID:28341898

Effect of Gevokizumab on Interleukin-1β-Mediated Cytochrome P450 3A4 and Drug Transporter Repression in Cultured Human Hepatocytes., PMID:28260174

Future directions for new medical entities in osteoporosis., PMID:25432357

Biological agents in management of osteoporosis., PMID:25204309

Impaired bone resorption and woven bone formation are associated with development of osteonecrosis of the jaw-like lesions by bisphosphonate and anti-receptor activator of NF-κB ligand antibody in mice., PMID:25173134

RANKL, a necessary chance for clinical application to osteoporosis and cancer-related bone diseases., PMID:24147256

Role of RANKL/RANK in primary and secondary breast cancer., PMID:24147253

Anti-RANKL antibody was approved for the treatment of osteoporosis in Japan., PMID:23994799

[Treatment of bone metastasis by denosumab, the human monoclonal neutralizing antibody to RANKL]., PMID:23259391

[Current approaches in multiple myeloma and other cancer-related bone diseases]., PMID:22549292

[Pharmacologic treatment of osteoporosis--2011]., PMID:21824859

[Involvement of RANKL/RANK pathway in bone metastasis in breast cancer]., PMID:21814020

[Osteoporosis and RANKL signal]., PMID:21814019

[Mechanism and strategy for treatment of cancer metastasis to bone]., PMID:21677475

[Animal models for bone and joint disease. RANKL-injected bone loss model]., PMID:21289416

RANKL inhibition for the management of patients with benign metabolic bone disorders., PMID:19558335

Prevention of glucocorticoid-induced bone loss in mice by inhibition of RANKL., PMID:19404943

Clinical applications of RANK-ligand inhibition., PMID:19356186

Comparison of the effect of denosumab and alendronate on BMD and biochemical markers of bone turnover in postmenopausal women with low bone mass: a randomized, blinded, phase 3 trial., PMID:18767928

Inflammation-induced bone loss: can it be prevented?, PMID:17288976

Document Download

Anti-Denosumab Neutralizing Antibody ELISA kit.pdf